Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5952W HIGH $1.72
Volume
1.43 M
Value Traded
594.13 K
Short % Float
0.65%
Days to Cover
2.5
+1.86%Week
-19.9%1 Month
-29.44%3 Month
-34.64%6 Month
-82.3%5 Year
-92.37%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
239.92 M
EPS (TTM)
0.22
P/E Ratio
2.83
Ent. Value
-237.13 M
Total Shares
392.78 M
Float Shares
378.61 M
Insiders
4.08%
Institutions
74.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
LAB Catalyst Timeline
Dated clinical, regulatory and corporate events for Standard BioTools Inc.
Past FDA Catalysts and PDUFA Decisions
How LAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Standard BioTools Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kim Hanjoon AlexOfficer (Chief Financial Officer) | Disposition | -18,871 2,760,530 held | $1.00 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 3.7 % (-40.3 %) | 73.04 M | 88.78 M |
Ownership Trends
LAB Short Interest
Shares sold short, counted twice a month.
0.65%
Short % of Float
of tradable shares sold short
2.4M
Shares Sold Short
-3.0% vs prior count
2.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
979.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LAB ranks across every disease it competes in
Competitive Position is a premium feature
See how LAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLAB News
LAB▼ -5.4%on this news
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
Standard BioTools Inc. has announced a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in about 30 days, pending customary conditions. CEO Michael Egholm expressed optimism about the future growth and innovation of the business under ARCHIMED's ownership.
Read more →LABStandard BioTools Provides Update on Sale of Mass Cytometry Business
Standard BioTools Inc. has announced the termination of its sale agreement with Multiplex Bio and has entered into a new agreement to sell its Mass Cytometry business to Element Biosystems for $5.5 million. This decision follows an unsolicited proposal from GMT Venture, which led the Board to conclude that the new offer was superior. The transaction is expected to close by the end of 2026, pending stockholder approval.
Read more →LABStandard BioTools Reports Second Quarter 2026 Financial Results
Standard BioTools Inc. reported its second quarter 2026 financial results, revealing a revenue of $20.1 million, a 7.6% decline from the previous year. Despite this, the company noted an 84% improvement in adjusted EBITDA. The anticipated merger with Treeline Biosciences is progressing, with expectations to close by year-end 2026. However, the company has withdrawn its full year revenue outlook due to the merger.
Read more →LABStandard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio, ensuring continuity of product lines and customer relationships. The company also received a $30 million buyout related to Illumina's acquisition of its SomaLogic business. Additionally, the U.S. FTC has terminated the waiting period for the merger with Treeline Biosciences, with both transactions expected to close by the end of 2026.
Read more →LAB▼ -7.4%on this news
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Standard BioTools Inc. has announced the publication date for its second quarter 2026 financial results, which will be released on August 5, 2026, after the U.S. market closes. The company aims to lead in the life science tools sector through innovation and operational excellence. Their products are designed to assist researchers in developing therapeutics more efficiently.
Read more →LAB▼ -5%on this newsshared move
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Standard BioTools has filed a registration statement for its merger with Treeline Biosciences, expected to close in the second half of 2026. The combined entity will have over $900 million in cash and a robust clinical pipeline, including promising data for TLN-121 in lymphoma. Industry veteran Sue Desmond-Hellmann has joined Treeline's Board of Directors.
Read more →LAB▼ -30.2%on this news
Standard BioTools and Treeline Biosciences Announce Combined company to operate as Treeline
Standard BioTools Inc. and Treeline Biosciences, Inc. have announced a merger agreement in an all-stock transaction. The merger aims to consolidate resources and expertise, creating a combined company named Treeline Biosciences. With an expected cash balance of over $900 million at closing, the newly formed company will have a solid financial foundation to pursue its pipeline of small molecule inhibitors and other therapies. The transaction is anticipated to close in the second half of 2026, following necessary approvals.
Read more →LABStandard BioTools Reports First Quarter 2026 Financial Results
Standard BioTools Inc. reported its financial results for Q1 2026, showcasing a revenue of $21.1 million, reflecting a 5% increase from the previous year. The company achieved a 54% reduction in operating loss and a 78% improvement in adjusted EBITDA, indicating progress towards profitability. Despite challenges in instruments revenue, the overall financial health appears strong with substantial cash reserves to support future growth.
Read more →LABStandard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
Standard BioTools Inc. has announced the release date for its first quarter 2026 financial results, which will be published on May 5, 2026, after the U.S. market closes. The company specializes in next-generation technologies that aid biomedical research, particularly in oncology and immunology. This announcement reflects the company's ongoing commitment to transparency and investor engagement.
Read more →LABStandard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Standard BioTools Inc. reported strong financial results for Q4 and full year 2025, highlighting better-than-expected performance and operational efficiencies. The company anticipates revenue between $80 million and $85 million for fiscal year 2026. The strategic sale of SomaLogic to Illumina is expected to provide flexibility for future growth, although risks remain regarding integration and market conditions.
Read more →LABStandard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. has announced that it will release its fourth quarter and full year 2025 financial results on February 24, 2026, after the U.S. market closes. The company is known for its advanced technologies that assist biomedical researchers in developing better medicines. Their focus includes oncology, immunology, and immunotherapy, serving various research institutions globally.
Read more →LABStandard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million. The transaction is expected to enhance Standard BioTools' financial position, allowing for future growth and acquisitions. However, the company faces risks related to stockholder litigation and the realization of expected benefits.
Read more →LAB▲ +20.3%on this news
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Standard BioTools announced preliminary revenue results for the fourth quarter and full year 2025, reporting approximately $185 million in total revenue. The company exceeded its expectations and highlighted steady execution under its strategic goals. With plans to finalize the sale of SomaLogic to Illumina, Standard BioTools projects a significant cash position and aims for positive adjusted EBITDA in 2026. The results, however, are preliminary and will be adjusted following the completion of audits, with inherent risks related to integration and business performance acknowledged.
Read more →LABStandard BioTools Reports Third Quarter 2025 Financial Results
Standard BioTools Inc. reported its third quarter financial results for 2025, highlighting a strong performance and a focus on operational efficiency. The company is implementing a restructuring plan aimed at achieving over $40 million in annual cost savings by 2026. Despite workforce reductions, the outlook remains positive with expected revenue between $165 million and $175 million for the fiscal year.
Read more →LABStandard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Standard BioTools Inc. announced it will publish its third quarter financial results on November 4, 2025, after the market closes. As a leading solutions provider, the company utilizes advanced technologies to aid biomedical researchers in accelerating the development of better medicines. Their proprietary methodologies are essential in various fields including oncology and immunotherapy, reflecting their commitment to improving patient outcomes.
Read more →LABStandard BioTools Reports Second Quarter 2025 Financial Results
Standard BioTools Inc. reported its financial results for the second quarter of 2025, registering total combined revenue of $42 million and revenue from continuing operations of $21.8 million. The company announced a strategic sale of SomaLogic to Illumina, potentially providing up to $425 million, which is anticipated to aid future growth. Operating expenses decreased by 11% year-over-year, showcasing improved financial management. Despite these positive aspects, the company experienced a 5% decline in revenue from continuing operations and ongoing market pressures.
Read more →LABStandard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
Standard BioTools has partnered with Precision Health Research, Singapore, to utilize its SomaScan 11K Assay for the PRECISE-SG100K study, which will analyze 100,000 plasma samples. This collaboration aims to enhance precision medicine and healthcare outcomes in Singapore by leveraging extensive participant data. The initiative is expected to set a new standard for population-scale proteomics.
Read more →LABStandard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
Standard BioTools Inc. will announce its second quarter 2025 financial results on August 11, 2025. A conference call will be held at 4:30 p.m. ET to discuss these results and the company's operational progress. The call will be accessible via phone and online webcast, with an archive available afterward.
Read more →LAB▲ +17.1%on this news
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
Standard BioTools has announced the strategic sale of SomaLogic to Illumina for up to $425 million, including $350 million upfront. This move aims to simplify the company's operations and achieve adjusted EBITDA break-even. The deal retains certain commercialization rights for Standard BioTools, positioning it for future growth. The transaction is expected to close in the first half of 2026, pending regulatory approvals.
Read more →LABStandard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
Standard BioTools Inc. has announced the launch of its inaugural Proteomics Roundtable Series, aimed at fostering discussions on advancements in proteomics. The first session will feature insights from researchers involved in a significant cancer study. Future sessions will cover various topics related to proteomic technologies and their applications in healthcare.
Read more →About Standard BioTools Inc.
Headquarters50 MILK STREET, BOSTON, MA, 02109
BIOPHARMAWATCH ELITE PLUS
Trade the next LAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime